Glioma

This study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.

This early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…

This study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…

This early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…

This early-stage trial tests a DNA vaccine called ITI-1001 in people with newly diagnosed glioblastoma, an aggressive brain cancer. The vaccine is designed to teach the immune system to recognize and attack cancer cells that carry common cytomegalovirus (CMV) proteins. About 10 p…

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…

This study tests whether Tofacitinib, a drug used for arthritis, can slow tumor growth in people with recurrent glioblastoma (a type of brain cancer). About 17 adults whose cancer returned after standard treatment will take Tofacitinib pills twice daily. The goal is to see if it …

This study tested whether adding the drug ZARNESTRA to standard radiation therapy can slow tumor growth in people with glioblastoma, an aggressive brain cancer. Twenty-seven patients took the drug daily starting a week before radiation and continuing through treatment. The main g…

This early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, …

This phase 1 study tested a drug called D2C7-IT in 81 adults with recurrent malignant glioma (a type of brain tumor). The drug is a lab-made antibody linked to a toxin that targets specific proteins on tumor cells. It was infused directly into the tumor over 72 hours using thin t…

This early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…

This phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…

This pilot study tested whether memantine, a drug used for dementia in adults, could help prevent memory and thinking problems in children receiving brain radiation for tumors like glioma or craniopharyngioma. 41 children aged 6-21 took either memantine or a placebo during radiat…

This early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug mig…

This early-phase study tested a method called convection-enhanced delivery to pump the chemotherapy drug topotecan directly into brain tumors in 16 patients with recurrent malignant brain tumors. The goal was to see if this approach is safe and to find the best dose, while also m…

This Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…

This study looked at adding the drug pazopanib to standard radiation or chemoradiation before surgery for patients with certain soft tissue sarcomas. The goal was to see if the combination is safe and helps shrink tumors more effectively. About 140 adults and children with newly …

This study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This pilot study tested a new approach for patients with recurrent high-grade glioma (grade 3 or 4 brain tumors) who have few options left. Researchers used a radioactive drug called 177Lu-PSMA to deliver radiation directly to tumor cells, after first checking if the tumors take …

This study tested whether adding the drug azeliragon to standard radiation and chemotherapy (temozolomide) is safe and shows early signs of working in people with newly diagnosed glioblastoma, a fast-growing brain cancer. 33 participants received the combination. The main goals w…

This study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…

This study tested a combination of two drugs, bevacizumab and temozolomide, given before standard chemoradiotherapy in 70 patients with newly diagnosed glioblastoma who had severe neurological symptoms. The goal was to reduce tumor size and improve symptoms enough to allow patien…

This pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …

This early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…

This phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…

This study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…

This study tested whether adding an immunotherapy drug called APX005M to standard chemotherapy (doxorubicin) could help shrink tumors in people with advanced soft tissue sarcoma. 27 adults with certain sarcoma types took part. The goal was to see if the combination was safe and w…

This phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) in 35 adults with recurrent or progressive IDH mutant gliomas that had been previously treated with alkylating agents. The main goal was to see if the drug could shrink tumors. The study is now complete, and resu…

This early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …

This study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…

This early-phase trial tested a new drug called obitazidine (SM-1) combined with the chemotherapy temozolomide in 35 adults with recurrent high-grade gliomas, a type of aggressive brain cancer. The main goal was to find a safe dose and check for side effects, while also looking f…

This early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for…

This study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…

This early-phase study tested whether adding the experimental drug ruxolitinib to standard radiation and chemotherapy (temozolomide) is safe for people with newly diagnosed high-grade gliomas or glioblastoma. Ruxolitinib targets proteins that help cancer cells grow. The study enr…

This study tested a special vaccine made from the child's own immune cells (dendritic cells) to fight aggressive brain tumors like high-grade glioma and DIPG. Ten children received the vaccine alongside standard treatments. The goal was to see if the vaccine was safe, possible to…

This early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…

This study tested a new surgical technique in 12 patients with newly diagnosed glioblastoma, an aggressive brain cancer. Surgeons placed a tissue flap from the scalp into the brain tumor cavity to bypass the blood-brain barrier, which normally blocks many treatments. The main goa…

This early-phase trial tested whether giving two immunotherapy drugs (nivolumab and ipilimumab) before standard surgery, chemotherapy, or radiation is safe and feasible for people with Neurofibromatosis Type 1 who have a rare malignant peripheral nerve sheath tumor. Only 13 parti…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This phase 2 trial tested two drugs, selumetinib and sirolimus, in 21 people with advanced malignant peripheral nerve sheath tumors (MPNST), a rare cancer often linked to neurofibromatosis type 1. The goal was to see if the combination could shrink or stabilize tumors. The study …

This early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…

This early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…

This study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…

This early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…

This study tested a drug called pamiparib, given with radiation therapy, for people with a fast-growing brain cancer called glioblastoma. It included 50 patients, some newly diagnosed and some whose cancer had come back. The goal was to see how much drug reaches the tumor and whe…

This study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…

This early-stage study tested two drugs, cabozantinib and pamiparib, together in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes t…

This early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …

This early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…

This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…

This study tested a combination of two chemotherapy drugs (BCNU and TMZ) given before radiation therapy in 53 people newly diagnosed with a rare type of brain cancer called anaplastic oligodendroglioma. The goal was to see how well the drugs shrank tumors and to learn more about …

This early-phase trial tested a new drug called KL340399, which is injected directly into tumors to activate the immune system. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if…

This early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway to help the immune system fight cancer. The main goals were to check safety, find th…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers like breast, ovarian, stomach, colorectal, brain, bile duct, or pancreatic cancer that had stopped responding to standard treatments. The goal was to see if the combo c…

This phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…

This early-phase study tested a personalized vaccine made from a patient's own immune cells (dendritic cells) combined with standard chemotherapy (temozolomide) for adults with newly diagnosed glioblastoma, an aggressive brain cancer. Eleven patients who had most of their tumor r…

This early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…

This study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…

This study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …

This study looked at whether giving chemotherapy after radiation helps children with a type of brain tumor called ependymoma. About 479 children aged 1 to 21 took part. Some received radiation alone, while others also got a combination of chemotherapy drugs. The goal was to see i…

This early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…

This early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…

This early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…

This completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…

This study tested a combination of two drugs, cobimetinib and atezolizumab, in children and adults with advanced soft tissue sarcoma that has spread. The goal was to see if the combo is safe and can stop tumors from growing. About 229 people took part, and researchers measured ho…

This study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…

This phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…

This early-phase study tested whether pumping the chemotherapy drug topotecan directly into the brain is safe for people with recurrent high-grade gliomas (aggressive brain tumors). Only 5 patients took part, and the main goal was to find a safe dose. The drug was delivered conti…

This study compared standard radiation plus chemotherapy to radiation plus two immunotherapy drugs (ipilimumab and nivolumab) in 159 people with a newly diagnosed, aggressive brain cancer called MGMT-unmethylated glioblastoma. The goal was to see if the immunotherapy combination …

This phase 2 trial tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy (temozolomide) improves survival in 47 adults with newly diagnosed glioblastoma or gliosarcoma. Participants had their tumors surgically removed and completed init…

This early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…

This small study tested whether a device using focused ultrasound can safely open the blood-brain barrier in patients with high-grade glioma (a type of aggressive brain cancer). The goal was to allow standard chemotherapy to reach the tumor more effectively. Only 3 patients were …

This early-phase study tested whether a 4-month ketogenic diet (a high-fat, low-carb diet) is safe and doable for people with newly diagnosed glioblastoma, a serious brain cancer. Twenty-one adults followed personalized meal plans while receiving standard radiation and chemothera…

This phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…

This study tested whether adding the immunotherapy drug durvalumab to targeted radiation can help people with recurrent glioblastoma, an aggressive brain cancer that has come back after initial treatment. The trial enrolled 108 adults and first checked safety, then randomly assig…

This study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…

This small pilot study tested whether combining focused ultrasound with a second round of radiation is safe for people with recurrent glioblastoma, an aggressive brain cancer. Seven adults who had already tried standard treatments received the combination therapy. The goal was to…

This pilot study tested a device called NaviFUS that uses focused ultrasound to temporarily open the blood-brain barrier, combined with the drug bevacizumab (Avastin), in 6 patients with recurrent glioblastoma (a type of brain cancer). The goal was to see if the combination is sa…

This study tested whether adding a metabolic therapy program (fasting and a ketogenic diet) to standard treatment (chemoradiation and chemotherapy) is safe and feasible for people with glioblastoma, an aggressive brain cancer. The approach aims to starve cancer cells by lowering …

This early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…

This study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…

This phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…

This early-stage study tested a single injection of JL15003 in 17 adults whose glioblastoma brain cancer had returned after standard treatments. The main goal was to check safety and find the best dose, while also looking at whether the virus in the injection spreads in the body …

This study tested combinations of three immunotherapy drugs—tislelizumab, surzebiclimab, and alcestobart—in 147 adults with advanced solid tumors that had not responded to prior treatments. The goal was to find safe doses and see if the drugs could shrink tumors. The trial is now…

This study tested a device called Optune, which delivers electric fields to the brain, alongside radiation and chemotherapy for people newly diagnosed with glioblastoma, an aggressive brain cancer. About 981 adults took part. The goal was to see if adding Optune to standard treat…

This early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …

This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …

This study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…

This early-stage trial tested a radioactive drug called I-123 ATT001 in 7 adults with recurrent glioblastoma, a fast-growing brain cancer. The drug was given directly into the tumor cavity to see if it was safe and how it spread in the body. The study aimed to find the right dose…

This study tested a personalized vaccine made from a patient's own tumor cells and immune cells (dendritic cells) for people with newly diagnosed glioblastoma, an aggressive brain cancer. The goal was to see if the vaccine is safe and can help delay tumor growth. 76 participants …

This study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…

This study looked at whether a modified Atkins diet combined with intermittent fasting is possible and has any effect in 25 people with glioblastoma, an aggressive brain cancer. Participants followed the diet for several weeks while researchers checked if they could stick with it…

This study tested a device that uses sound waves and tiny bubbles to temporarily open the blood-brain barrier in 28 people with recurrent glioblastoma, a type of brain cancer. The goal was to see if it is safe and feasible to let the chemotherapy drug carboplatin reach the tumor …

This study tested whether a device called ExAblate, which uses focused ultrasound, can safely open the blood-brain barrier in 20 people with high-grade glioma (a type of brain cancer). The goal was to allow standard chemotherapy to reach the tumor more effectively. Researchers ch…

This early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…

This early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…

This early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…

This early-phase trial tested a combination of two drugs—fluvastatin (a cholesterol-lowering statin) and celecoxib (an arthritis drug)—in 20 children and young adults with certain brain tumors (gliomas) that had come back or not responded to treatment. The goal was to find the sa…

This study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…

This study tested a drug called AB-218 (safusidenib) in 14 adults with a specific type of slow-growing brain tumor (IDH1 mutated low grade glioma) who were already scheduled for surgery. The goal was to see if it's possible to measure how much drug gets into the tumor and to chec…

This study tested a new drug called BI 3706674 in 47 adults with advanced stomach or esophageal cancer that had not responded to prior treatment. The drug is a tablet that blocks growth signals in cancer cells. The main goals were to find a safe dose and see if the drug could shr…

This early-phase study tested whether adding the drug cilengitide to standard radiation is safe for children and young adults with a rare, aggressive brain tumor called DIPG. The main goal was to find the highest safe dose. 32 participants were enrolled. The study did not aim to …

This phase 2 trial tested the drug crizotinib in 12 people with neurofibromatosis type 2 (NF2) who had growing tumors in the ear area called vestibular schwannomas. Participants took crizotinib pills daily for up to 12 months. The main goal was to see if the drug could shrink the…

This early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…

This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…

This early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …

This early-phase study tested the safety of combining two drugs—AZD1775 (a pill) and durvalumab (an IV infusion)—in 56 adults with advanced solid tumours that had stopped responding to standard treatments. The goal was to find safe doses and watch for side effects. While not a cu…

This study tested an experimental drug called ENV-101 (taladegib) in 20 adults with advanced solid tumors that have a specific genetic mutation (PTCH1 loss-of-function). The drug works by blocking a growth pathway in cancer cells. Researchers measured how many patients' tumors sh…

This completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…

This completed Phase III trial tested a drug called 5-aminolevulinic acid (5-ALA) in 86 adults with malignant brain glioma. Patients took the drug orally before surgery, causing tumor cells to glow under a special light. This helps surgeons see and remove more cancerous tissue. T…

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This study tested the safety and effectiveness of the drug abemaciclib combined with other cancer medicines in 47 children and young adults whose solid tumors (including neuroblastoma) had stopped responding to standard treatments. The goal was to find the best dose and see if th…

This early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…

This early-phase trial tested a new treatment for aggressive brain tumors called high-grade glioma. Sixteen patients received a drug (5-ALA) plus focused ultrasound to activate the drug inside the tumor, a few days before standard surgery and chemo-radiation. The main goal was to…

This study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …

This study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…

This early-phase study tested a combination of two drugs (low-dose capecitabine and bevacizumab) in 12 people whose glioblastoma brain tumor had come back or continued growing despite prior treatment. The goal was to see if the drugs could reduce certain immune cells (MDSCs) that…

This early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…

This early-phase trial tested an oral drug called AG-120 in 174 people with advanced solid tumors (including bile duct cancer, cartilage cancer, and brain tumors) that have a specific IDH1 mutation. The study first found a safe dose, then expanded to see how well the drug works. …

This early-phase study tested two experimental drugs, AG-120 and AG-881, in 49 adults with a recurrent, slow-growing brain tumor (low grade glioma) that has a specific IDH1 gene mutation. The goal was to see if these drugs could lower a substance called 2-HG in the tumor tissue b…

This study tested two or three drugs together in adults with advanced solid tumors (cancers that have spread). The main goal was to find the safest dose and see if the combination can shrink tumors. Participants took brigimadlin pills and received ezabenlimab infusions every 3 we…

This early-phase study tested an oral drug called AG-881 in 95 adults with advanced solid tumors, including brain tumors (gliomas), that have specific IDH gene mutations. The main goals were to check safety, find the best dose, and see how the drug works in the body. While not a …

This study tested a wearable device called NOVOTTF-200A in people with recurrent Grade III astrocytoma, a type of brain cancer. The device delivers low-intensity electric fields to the brain to slow tumor growth. Only 1 participant was enrolled, and the main goal was to see if th…

This early-phase trial tested an mRNA vaccine called CVGBM in 37 people with a fast-growing brain cancer called glioblastoma. Participants had already had surgery and radiation. The vaccine aims to train the immune system to attack remaining cancer cells. The main goal was to che…

This phase 2 trial tested a gel called NFX-179 on skin tumors in 199 adults with neurofibromatosis type 1. Participants applied the gel daily for 26 weeks. The study measured safety and whether tumors shrank in size or height. Results suggest the gel may help reduce tumor volume,…

This early-phase study tested a drug called Tovorafenib in 44 children with low-grade gliomas (a type of brain tumor) that had come back or continued growing despite other treatments. The main goal was to find the safest dose and check for side effects. The drug works by blocking…

This early-phase study tested a new drug called AMG 305 in 37 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Participants received the drug and were mo…

This pilot study tested whether it's possible to quickly create and start a personalized drug combination for each patient with recurrent glioblastoma, a serious brain cancer. Researchers used genetic testing on tumor tissue to pick drugs that target specific mutations. The study…

This early-phase trial tested whether adding THC and CBD (cannabinoids from cannabis) to standard chemotherapy and radiation is safe for people with newly diagnosed glioblastoma, an aggressive brain cancer. Thirty-three patients received gradually increasing doses of the cannabin…

This early-phase study tested a new drug called CUDC-907 in 26 children and young adults (ages 1-21) with cancers that had come back or stopped responding to treatment, including solid tumors, brain tumors, and lymphoma. The main goal was to find a safe dose and check for side ef…

This early-phase trial tested two experimental drugs, FdCyd and THU, taken by mouth for advanced solid tumors that had not responded to standard treatments. Fifty-nine adults received the drugs in 21-day cycles to see if they were safe and tolerable. The goal was to find a dose f…

This pilot study tested whether a light-activated drug (5-ALA) could be safely used during brain surgery to treat glioblastoma, an aggressive brain cancer. Ten adult patients received this experimental therapy in addition to standard surgery and chemoradiation. The main goal was …

This study tested a new pill called larotrectinib in 75 adults with advanced cancers that have a specific gene change (NTRK fusion). The main goals were to check the drug's safety, find the best dose, and see how the body processes it. Participants had no other good treatment opt…

This early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…

This early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs th…

This early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…

This early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…

This early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…

This study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…

This early-stage study tested the drug revumenib in 42 adults with colorectal cancer or other solid tumors that had spread or come back after at least one prior treatment. The goal was to see if the drug is safe and can slow tumor growth. Researchers measured side effects, how th…

This study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…

This phase 3 trial tested whether giving only PCV chemotherapy, instead of chemotherapy plus radiotherapy, could protect thinking abilities in people with a specific brain tumor (1p/19q codeleted anaplastic glioma). 280 newly diagnosed adults were randomly assigned to receive eit…

This pilot study tested a new type of immune cell therapy called anti-ALPP CAR-T cells in 5 patients with advanced solid tumors that have a specific marker (ALPP). The goal was to see if the treatment is safe and can shrink tumors. Patients first received chemotherapy to prepare …

This early-phase study tested whether a focused ultrasound device can safely open the blood-brain barrier in 13 adults with recurrent glioblastoma, a severe brain cancer. The goal was to let the chemotherapy drug carboplatin reach the tumor more effectively. The study focused on …

This early-phase study tested a new type of immunotherapy called ALPP CAR-T cells in 5 adults with advanced solid tumors that had not responded to standard treatments. The therapy involves genetically modifying a patient's own immune cells to recognize and attack cancer cells tha…

This early-phase study tested an experimental drug called BMS-986288, both by itself and combined with the immunotherapy nivolumab (Opdivo), in 219 people with advanced solid tumors that had worsened after standard treatments. The main goal was to check safety and tolerability, a…

This early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…

This study tested a drug called avapritinib in 29 children aged 2 to 18 with advanced solid tumors that have specific genetic changes (KIT or PDGFRA). The goal was to see if the drug is safe and can shrink or control the tumors. Participants took the drug by mouth, and researcher…

This study tested a new drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments or had no standard …

This early-phase study tested a new drug called JAB-8263 in 41 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study is now complete.

This early-phase trial tested adding the targeted drug regorafenib to standard chemotherapy (temozolomide) with or without radiation for people with a newly diagnosed, aggressive type of brain cancer called glioblastoma. The study involved 21 participants and aimed to find the sa…

This early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…

This early-phase trial tested an experimental drug called ADG116, which helps the immune system attack cancer cells. The study included 72 adults with advanced solid tumors that had stopped responding to standard treatments. Some participants received ADG116 alone, while others g…

This early-phase study tested an experimental drug called INCB7839 in 13 children whose high-grade gliomas (aggressive brain tumors) had come back or worsened after standard treatment. The main goals were to find a safe dose and check for side effects. The drug works by blocking …

This early-phase trial tested a new drug called FL115 in 18 adults with advanced solid tumors that had stopped responding to standard treatments. FL115 is designed to strengthen the body's immune cells to fight cancer. The main goal was to check safety and find the right dose, wh…

This study tested a new drug called IBI334 in 28 people with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to check the drug's safety and see if it helps control the cancer. The study is now complete.

This early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…

This early-phase study tested an experimental drug called JAB-BX102, alone or with the immunotherapy pembrolizumab, in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also …

This early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose for future studies. This is not a cure, but a step toward better control…

This early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …

This study tested giving a second round of radiation to people whose glioblastoma (a fast-growing brain tumor) came back after standard treatment. Seventeen adults aged 18 to 50 received daily radiation for 2-3 weeks. The goal was to find the safest highest dose and see how it af…

This trial tested a two-step treatment for people with advanced solid tumors that no longer respond to standard therapies. First, a laser heats and destroys part of the tumor. Then, a drug called IP-001 is injected directly into the treated area to help the immune system recogniz…

This early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked …

This early-phase study tested a new oral drug called LP-118 in 68 people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. LP-118 works by blocking two proteins that help cancer cells survive. The main goals were to find a safe dose and c…

This phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.

This early-phase study tested a combination of tumor treating fields (a device that creates electric fields to disrupt cancer growth), stereotactic radiosurgery (precise radiation), and temozolomide chemotherapy in 12 adults with newly diagnosed glioblastoma. The main goal was to…

This study tested a new way to guide brain surgery for glioblastoma, a fast-growing and hard-to-treat brain cancer. Doctors used artificial intelligence (AI) to create maps showing where the tumor is likely to come back, then removed extra tissue beyond the visible tumor. The goa…

This early-phase trial tested a new drug called NB003 in 258 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. The study is now complete, an…

This study tested an injectable drug called RC88 in 41 people with advanced solid tumours who had no other good treatment options. The main goal was to check the drug's safety and find the right dose. The study is now complete, and results will help guide future research.

This early-phase study tested a new daily pill, ASC61, in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and how the body processes it. Researchers looked for side effects and measured tumor respons…

This early-stage trial tested a new oral drug, JNJ-64619178, in 114 people with advanced cancers (including solid tumors, lymphoma, and myelodysplastic syndromes) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effect…

This early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…

This early-phase study tested a new drug called RO7623066, given alone or with other treatments, in 116 adults with advanced solid tumors that had not responded to prior therapies. The main goals were to find the safest dose and check for side effects. While not a cure, the study…

This early-stage study tested a new treatment for children and young adults with brain tumors that came back or didn't respond to standard therapy. Doctors took the patients' own immune cells, modified them to recognize a protein called EGFR on tumor cells, and injected them dire…

This early-phase study tested an experimental drug called E7090 in 40 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find the safest dose and check for early signs of effectiveness, especially in patients whose tumors have certain…

This early-phase study tested a new drug called tinostamustine in 10 people with a specific type of glioblastoma, a severe brain cancer. The drug was given after standard treatment to see if it is safe and to find the right dose. The goal is to control the disease and delay its r…

This early-phase study tested a new drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for early…

This early-phase trial tested a new drug called BAT6026 in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body …

This early-stage study tested a new drug called BAT1308 in 59 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body. Th…

This phase 2 trial tested whether increasing the light dose during a special type of therapy called photodynamic therapy (PDT) is safe for people with glioblastoma, an aggressive brain cancer. Fourteen patients received a drug (5-ALA) before surgery, then a red laser was shone on…

This early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…

This early-phase study tested a combination of two experimental drugs (AK127 and AK104) in 67 people with advanced or metastatic solid tumours that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking for s…

This early-phase study tested a new drug called TG02 in 71 patients with aggressive brain cancers (anaplastic astrocytoma or glioblastoma). The goal was to find the safest dose when combined with either radiation or chemotherapy. The study included newly diagnosed elderly patient…

This study tested a new vaccine called EO2401 in 100 adults with glioblastoma that had come back after standard treatment. The vaccine was given alone or with other drugs to see if it was safe and could help the immune system fight the cancer. The goal was to find better ways to …

This study tested a new drug (LY2157299) alone or combined with standard chemotherapy (lomustine) in 158 adults with recurrent glioblastoma, an aggressive brain cancer. The goal was to see if the new drug could help patients live longer or slow tumor growth compared to chemothera…

This early-stage trial tested a new drug, GEN1056, in 26 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked for signs that the drug might shrink tumors.

This phase 2 trial tested a combination of two drugs (retifanlimab and epacadostat) plus radiation and bevacizumab in 51 patients with recurrent glioblastoma, an aggressive brain cancer. The goal was to boost the immune system's attack on the tumor and improve survival. The study…

This early-phase trial tested a new drug called BR101 in 15 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it shows any signs of shrinking tumors. Participants receiv…

This Phase 3 trial tested whether giving chemotherapy based on the specific type of soft tissue sarcoma works better than a one-size-fits-all approach. 550 adults with high-risk sarcomas in the arms or trunk were randomly assigned to standard chemo or a chemo regimen matched to t…

This study tested an experimental drug called BMS-986249, either alone or combined with the immunotherapy nivolumab (Opdivo), in 356 people with advanced solid tumors. The main goals were to check safety and find the right dose. Researchers also looked at whether the tumors shran…

This early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …

This study tested whether adding whole brain radiation and a drug called plerixafor to the usual chemotherapy and radiation could help people with a fast-growing brain tumor called glioblastoma. 21 patients took part. The goal was to see if the combination could delay tumor growt…

This early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…

This early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…

This early-phase study tested a new immunotherapy drug called BDB018, given alone or with pembrolizumab, in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Only one person took part, …

This early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…

This early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy pembrolizumab (KEYTRUDA), in 182 adults with advanced solid tumors, including lung and breast cancers. The main goals were to check safety and how the drug moves…

This early-phase trial tested a new drug called HCW9218 in 18 people with advanced solid tumors that had not responded to at least two prior treatments. The drug is designed to both activate immune cells and block signals that help tumors grow. The main goal was to find a safe do…

This study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…

This study tested a new drug called DF9001, which helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (pembrolizumab) to 24 adults with advanced solid tumors that have the EGFR protein. The goal was to check safety and find …

This early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…

This study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkag…

This phase 1 trial tested a combination of two drugs, ASP8374 and cemiplimab (Libtayo), in 14 people with recurrent malignant glioma, a type of brain cancer. The study had two parts: first, finding the safest dose of ASP8374 when given with cemiplimab, and second, checking how th…

This early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including non-small cell lung cancer. The drug works by activating immune cells to fight cancer. The main goals were to check safety, find the best dose, and see how the drug move…

This early-phase trial tested a new antibody drug called AGEN1777, given alone or with another antibody (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and se…

This early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and s…

This early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This Phase 3 trial tested whether adding a cell therapy called Immuncell-LC to standard chemotherapy (temozolomide) helps people with newly diagnosed glioblastoma, an aggressive brain cancer. The study enrolled 180 patients in Korea who had surgery for glioblastoma. Researchers m…

This early-phase trial tested the safety of adding two drugs, pembrolizumab and vorinostat, to standard chemotherapy and radiation for people newly diagnosed with glioblastoma, an aggressive brain cancer. The study enrolled 21 participants to find the highest safe dose of vorinos…

This early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study …

This early-stage study tested a new drug (BI 836880) alone and with another drug (BI 754091) in 21 Japanese patients with advanced solid tumors. The main goal was to find the safest dose and check for side effects. This is not a cure, but a step toward better controlling advanced…

This early-phase study tested a new drug called AMG 256 in 34 adults with advanced solid tumors that could not be cured by standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Researchers monitored side effects and how the…

This study tested a drug called MEK162 in 105 children with low-grade gliomas or other tumors that have a specific overactive growth signal. The goal was to find the best dose, check for side effects, and see if the drug could shrink tumors. Children took the drug by mouth twice …

This early-phase study tested a combination of two immunotherapy drugs, BGB-A445 and tislelizumab, in 204 people with advanced solid tumors including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. The trial is now comp…

This early-phase trial tested an experimental drug called BMS-986408, alone or combined with the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to chec…

This study tested the drug lenvatinib in 127 children, adolescents, and young adults whose solid tumors had come back or stopped responding to treatment. The goal was to see if the drug could shrink tumors and to check for side effects. Participants received lenvatinib daily, and…

This study tested a precise type of radiation called proton beam therapy for people whose cancer has spread to the liver. 92 adults with 1 to 4 liver tumors received this treatment. The goal was to see if it could stop tumor growth and cause fewer side effects than standard radia…

This early-phase trial tested a new drug called BI 836880 in 24 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Researchers also looked at how the drug moves through the bo…

This early-phase trial tested a new drug called BI 836880 in 29 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to find a safe dose and check for side effects. The study was not designed to cure cancer, but to gather information …

This early-phase trial tested two experimental drugs, BNT152 and BNT153, alone and together in 86 adults with advanced solid tumors that had spread or could not be removed and had no standard treatment options. The main goal was to check safety and find the best dose. Researchers…

This early-phase study tested an experimental drug called ABBV-CLS-579, given alone or with other cancer treatments, in 101 adults with advanced solid tumors that had stopped responding to standard therapy. The main goal was to find safe and tolerable doses, not to prove the drug…

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy and radiation helps people with newly diagnosed glioblastoma, an aggressive brain cancer. About 60 participants received the combination to see if it improves survival and controls the d…

This early-phase study tested a combination of three drugs—selinexor, nivolumab, and ipilimumab—in 11 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The main goal was to check the safety and tolerability of the combination, whi…

This study tested whether a dye called 5-ALA, which makes tumor cells glow during surgery, helps surgeons remove more of a deadly brain cancer called glioblastoma. 170 adults with newly diagnosed glioblastoma were randomly assigned to receive either 5-ALA or a placebo before surg…

This study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 37 Chinese patients with advanced solid tumors that had not responded to prior treatment. The main goals were to check safety and see if the drugs could shrink tumors. The trial is now comple…

This early-phase trial tested a new drug called RiMO-301, injected directly into tumors, along with standard radiation. It involved 32 people with advanced cancers that could not be cured. The main goal was to find a safe dose and check for any early signs of tumor shrinkage.

This phase 2 study tested the drug olaparib in 35 people with recurrent IDH-mutant high-grade gliomas, a type of brain tumor. The goal was to see if olaparib could stop the tumor from growing for at least 6 months. Participants took olaparib tablets twice daily until their diseas…

This early-phase study tested an experimental drug called TPST-1495, taken as a pill, either alone or combined with the immunotherapy Keytruda (pembrolizumab). The trial included 89 people with advanced solid tumors like colorectal, lung, head and neck, and endometrial cancers wh…

This early-phase trial tested an experimental drug called LM-108, alone or combined with another immunotherapy, in 78 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers als…

This early-phase trial tested a new radioactive drug called 177Lu-LNC1004 in 11 adults with advanced solid tumors that had stopped responding to standard treatments. The drug targets a protein (FAP) found on many cancer cells, delivering radiation directly to the tumor. The main …

This study tested the drug everolimus in 65 children whose low-grade gliomas had come back or worsened. The goal was to see if the drug could stop or slow tumor growth. Children took everolimus pills daily, and doctors tracked tumor changes with MRI scans. The study focused on ho…

This phase 2 trial tested a drug called VAL-083 combined with standard radiation in 29 people with newly diagnosed glioblastoma, a fast-growing brain cancer. The study focused on patients whose tumors have a specific genetic marker (unmethylated MGMT) that makes them resistant to…

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…

This early-stage trial tested an experimental drug called EVT801 in 32 adults with advanced solid tumours that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose to use in future studies. Participants took EVT801 cap…

This early-stage trial tested whether adding chlorpromazine, an old antipsychotic drug, to standard treatment (radiation and chemotherapy) is safe for people newly diagnosed with glioblastoma, an aggressive brain cancer. Ten adults took part. The main goal was to find a safe dose…

This study tests whether an artificial intelligence system called GliomaAI-Astro23 can identify a specific type of brain tumor (IDH mutant astrocytoma) from routine MRI scans. Researchers are using existing MRI data from 1,372 patients to train and evaluate the AI. If accurate, t…

This study tests whether an artificial intelligence system called GliomaAI-Astro4 can accurately detect a specific type of brain tumor (IDH mutant astrocytoma grade 4) using routine MRI scans. Researchers will analyze previously collected, anonymized MRI data from 1,372 patients …

This study tests whether an artificial intelligence system called GliomaAI-GBM can detect a specific aggressive brain tumor (IDH wildtype glioblastoma) using routine MRI scans. Researchers will analyze previously collected, anonymized MRI data from 1,372 patients across 13 hospit…

This study tests whether an artificial intelligence system called GliomaAI-Oligo can detect a specific type of brain tumor (oligodendroglioma) from routine MRI scans. Researchers will use over 1,300 existing, anonymized scans from multiple hospitals to train and evaluate the AI. …

This early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…

This study tested an artificial intelligence system called GliomaAI-MG that analyzes routine MRI scans to detect a specific aggressive brain tumor type called molecular glioblastoma. Researchers used existing MRI data from 1,372 patients across 13 hospitals. The goal was to see h…

This study tests a special SPECT imaging agent that seeks out a protein called LRRC15, found on many aggressive cancers like pancreatic, breast, lung, and brain tumors. The goal is to see if this scan can help doctors diagnose and stage these cancers more accurately. Healthy volu…

This completed study tested whether combining PET/MRI scans with machine learning could better assess how aggressive prostate cancer and other solid tumors are. Researchers enrolled 50 adults with prostate cancer, liver cancer, brain tumors, or kidney cancer. The goal was to see …

This study looked at whether a special type of PET scan (using a tracer called FET) can accurately tell the difference between a returning brain tumor (glioma) and harmless changes caused by previous treatment. Researchers analyzed scans from 253 patients of all ages who had alre…

This study looked at whether a special PET scan using 18F-FDOPA can help doctors make better treatment decisions for people with brain tumors (gliomas or metastases) when standard MRI results are unclear. 85 patients whose MRI scans were inconclusive received this PET scan, and r…

This study tested a special PET scan tracer called FLT in 50 adults with brain tumors (gliomas or metastases). The goal was to see if FLT-PET can measure how fast tumor cells are growing, which could help doctors diagnose and predict tumor behavior better than current scans like …

This study tested whether a special dye called fluoroethyltyrosine (FET) can improve PET scans for detecting brain tumors that have come back. 143 people with suspected recurrent brain tumors received an injection of FET before their PET scan. The goal was to see if FET-PET could…

This completed Phase 3 trial tested whether Elucirem (gadopiclenol) provides better MRI images of brain gliomas compared to the standard contrast agent Dotarem. 138 adults with primary or recurrent brain tumors received one of the two agents during DSC-MRI perfusion scans. The ma…

This study tested a new MRI contrast agent called RVP-001, made with manganese instead of gadolinium, in 18 adults with known brain lesions (like tumors or multiple sclerosis). The goal was to see if it is safe and can detect lesions as well as current gadolinium-based dyes. Each…

This early study tested a special light probe that helps surgeons see brain tumor tissue during an operation. Eleven adults with suspected brain tumors took part. The probe uses a drug that makes tumor cells glow, and the goal was to see if the device could accurately tell tumor …

This study tested whether a special type of PET/MRI scan using a radioactive tracer called FET can better map glioblastoma brain tumors after surgery compared to standard MRI. The goal was to see if this could help doctors plan radiation therapy more accurately. Eleven adults who…

This early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …

This early-phase trial tested a new radioactive imaging agent called 68Ga-NOTA-SNA002 in 17 adults with solid tumors. The agent was injected into a vein, and researchers checked its safety, how it spreads in the body, and how well it shows up on PET scans. The goal was to see if …

This study tested a special MRI technique called diffusion tensor tractography (DTT) to map the facial nerve before surgery for vestibular schwannoma, a benign brain tumor. The facial nerve is at risk during surgery, and injury can cause permanent facial weakness. The study invol…

This early-phase trial tested a single injection of a radioactive imaging agent called 68Ga-LNC1007 in 8 adults (healthy volunteers and solid tumor patients). The goal was to check its safety, how it moves through the body, and how well it shows up on scans. The study is already …

This study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…

This study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…

This pilot study tested whether ramipril, a drug typically used for high blood pressure, can help prevent memory loss in people with glioblastoma who are receiving brain radiation. 75 patients took ramipril daily during and after chemoradiation. Researchers measured memory and th…

This study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…

This study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…

This study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…

This study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…

This study looked at whether video doctor visits (telehealth) work as well as in-person visits for people with brain tumors (gliomas) who are taking oral chemotherapy. 30 patients took part, alternating between telehealth and in-person checkups. The goal was to see which type of …

This pilot study tested a new way to deliver radiation therapy to people with recurrent IDH-mutant gliomas who had already received radiation to the brain. Instead of giving one large dose, the radiation was given in many small, timed pulses to reduce side effects. The study incl…

This pilot study tested a telehealth program called C-SMART for people with primary brain tumors who have mild memory or thinking problems. The program combines cognitive rehabilitation with mindfulness training over 8 weekly sessions. Researchers enrolled 32 patients and caregiv…

This study looked at whether taking statins (cholesterol-lowering drugs) can reduce hearing loss caused by platinum-based chemotherapy in people with solid tumors. 56 adults who were about to start chemotherapy took part. The goal was to see if statins could protect their ears fr…

This study tested whether using creams with niacinamide and shea butter can prevent or reduce skin itching in cancer patients receiving immunotherapy. 130 adults with solid tumors starting checkpoint inhibitor treatment were randomly assigned to use either the test cream or a con…

This study tested two stress and symptom management programs for adults with neurofibromatosis (NF1, NF2, or schwannomatosis). The programs were delivered through live videoconferencing over 8 weekly sessions. Researchers measured changes in quality of life and emotional well-bei…

This study tested a 12-week nursing program based on the Roy Adaptation Model in 160 adults who developed facial paralysis after surgery for a large acoustic neuroma. The program included education, counseling, and facial exercises, and aimed to reduce anxiety and depression whil…

This study tested whether Reiki, a relaxation therapy where a practitioner places hands on or near the body, could help cancer patients with symptoms like pain and fatigue. Ten adults with cancer who had at least three bothersome symptoms received up to six Reiki sessions. Resear…

This study tested a type of talk therapy called Cognitive Behavioral Therapy for Insomnia (CBT-I) in 70 people with brain tumors who also had trouble sleeping. The therapy involved six weekly group sessions delivered online. The main goal was to see if the approach was practical …

This study tested a web-based program to help children aged 8-17 with cancer adjust to returning to school. The program included modules for children, parents, teachers, and peers, focusing on communication, coping, and social skills. Twenty children participated, and researchers…

This study looked at whether monthly visits to a hospital day care that includes palliative care can improve quality of life for adults with advanced cancer. 144 patients with a life expectancy between 2 and 12 months took part. Researchers measured changes in quality of life, fa…

This study tested whether taking zinc supplements and applying a strong steroid cream (clobetasol) can prevent or reduce hand-foot skin reaction, a common and painful side effect of the cancer drug regorafenib. About 150 patients starting regorafenib were split into three groups:…

This study gathered information from 326 adults with rare central nervous system tumors, such as medulloblastoma and ependymoma. Participants completed surveys about their symptoms, treatments, and lifestyle, and provided a saliva sample for genetic analysis. The goal was to lear…

This study followed 17 adults with neurofibromatosis type 1 (NF1) over two years to learn how their skin tumors (dermal neurofibromas) grow and change. Researchers used special cameras and skin biopsies to measure tumor growth and look for genes that might influence it. The goal …

This study tests a new graphene-based electrode array used during brain tumor surgery to map brain activity. Ten participants will have the device used alongside standard monitoring to check its safety and how well it records brain signals. If awake during surgery, they may do si…

This study looked at people with neurofibromatosis type 1 (NF1) to better understand how harmless tumors (plexiform neurofibromas) turn into a rare cancer called MPNST. Ten participants had MRI, PET scans, and tumor biopsies. Researchers tested whether a special PET scan (FLT PET…

This study tests whether wearable sensors and digital home tasks can track changes in movement, speech, and falls in people with ALS. About 20 participants will wear neck and wrist sensors and complete speech and handwriting tests over 48 weeks. The goal is to see if these digita…

This completed study enrolled over 1,200 people with brain or spinal cord tumors to collect medical information, blood samples, and tumor tissue. The goal was to better understand these cancers and identify promising areas for future research. Participants also received guidance …

This study looked at whether a special type of PET scan (amino acid PET) can better measure how well IDH inhibitor drugs are working in patients with a certain type of brain tumor (IDH-mutated glioma). The researchers compared the PET scan results with standard MRI scans in 22 pa…

This completed study looked at whether a special PET scan technique called radiomics can help doctors figure out the type and behavior of brain tumors (gliomas) without needing a surgical biopsy. Researchers analyzed scans from 1000 patients who had already received an 18F-FDOPA …

This completed study surveyed 100 adults with brain tumors (gliomas) to understand how social factors like income, education, housing, and community support affect their health. Participants answered questionnaires about their neighborhoods, access to food and transportation, and…

This study looks at people with neurofibromatosis type 1 (NF1) and their families to find out why some have more severe symptoms than others. Researchers will collect medical history, blood samples, and images to study genes and physical traits. The goal is to identify genes that…

This study followed 76 children with brain tumors to learn how radiation therapy affects their quality of life, thinking, and body functions over time. Researchers collected blood, urine, and MRI scans before and after treatment, along with tests of memory, behavior, vision, and …

This study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…

This study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…

This study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…

This study looked at brain tumors (gliomas) in 128 patients under 25 treated at one French hospital. Researchers compared the genetic and imaging features of tumors in children (0-14 years) versus adolescents and young adults (15-25 years). The goal was to see if these groups hav…

This study reviewed medical records of 37 children under 18 diagnosed with rare brain tumors called DIA or DIG between 1996 and 2015 in French cancer centers. Researchers wanted to find out why some of these usually benign tumors become malignant. By analyzing clinical, genetic, …

This study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.

This study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…

This pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.

This study tested a new way of analyzing MRI scans, called activity MRI (aMRI), to see if it can measure brain tumor activity as well as PET scans. Four adults with glioma had both aMRI and standard PET imaging. The goal was to check if aMRI results match PET findings, which coul…

This study looked at whether whole genome sequencing of recurrent glioblastoma tumors can uncover more targeted treatment options. Researchers analyzed tumor samples from 164 patients who had surgery for their first recurrence. The goal was to see if this detailed genetic testing…

This study looked at memory complaints in 426 people, including those with brain tumors, breast cancer, and healthy volunteers. Participants filled out questionnaires about their memory, mood, and fatigue. The goal was to understand how cancer and its treatments might affect ever…

This study tested whether machine learning can detect cancer pain by analyzing facial expressions, voice, and speech. 83 people with cancer recorded videos at clinic visits and at home over 3 months. The goal was to see if this technology could classify pain levels in a diverse g…

This study tested a new imaging technique using a special substance (hyperpolarized carbon-13 alpha-ketoglutarate) to see how active brain tumors are in people with IDH mutant glioma. Twelve adults with this type of brain tumor received an injection and then had an MRI scan. The …

This completed registry followed nearly 8,000 adults with solid tumors who had next-generation sequencing (NGS) genetic testing. The goal was to collect real-world data linking test results, treatments, and survival. No new drug or intervention was tested; instead, the registry a…

This study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…

This study tested a special PET scan to measure oxygen levels inside glioblastoma brain tumors. Low oxygen (hypoxia) can make tumors harder to treat. The goal was to find the best way to use this scan to guide treatment. 14 adults with newly diagnosed glioblastoma took part.

This study developed and tested a program to help nurses better support relatives of patients with acquired brain injury or malignant brain tumors. The program included nurse training, a dialog tool, a peer support list, videos, and documentation guidelines. Researchers tested it…

This study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…

This study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…

This study looked at how the drug tuvusertib is absorbed, broken down, and removed from the body in 12 people with advanced solid tumors. Participants received a tiny radioactive tracer to track the drug. The main goal was to understand the drug's path in the body, not to treat t…

This study tested whether an 18F-FDOPA PET scan changes treatment decisions for people with high-grade gliomas (aggressive brain tumors) when standard MRI results are unclear. Researchers enrolled 110 patients and compared treatment plans before and after the scan. The goal was t…

This study tested a new type of MRI-like scan called Field Cycling Imaging (FCI) on 9 people who had surgery for low-grade gliomas. The goal was to see if FCI can tell apart different subtypes of these slow-growing brain tumors without needing another surgery or biopsy. Each part…

This study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…

This completed study looked at how re-irradiation affects the quality of life and symptoms of 20 children with diffuse intrinsic pontine glioma (DIPG) or recurrent brain tumors, as well as their caregivers. Researchers used surveys to track physical, emotional, and social well-be…

This study looked at whether a special MRI technique can identify the most aggressive parts of a glioblastoma brain tumor. Researchers took tissue samples from different areas of the tumor during surgery and tested them for cancer stem cells. The goal was to see if MRI markers ma…

This completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…

This study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…

This study looked back at medical records of 41 patients who had surgery for aggressive brain tumors (high-grade gliomas). Some surgeries used fluorescent dyes that make tumor tissue glow, helping surgeons tell it apart from healthy brain. The goal was to see if using these dyes …

This study looked at brain tissue from 20 glioblastoma patients who had received Tumor Treating Fields (TTFields) therapy. Researchers examined the tissue after the patients died to see how the treatment affected tumor cells. The goal was to find patterns that could help doctors …

This study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…

This study tested a new type of MRI scan that shows how brain tumors use energy, which could help doctors make better treatment decisions. Seventeen adults with glioblastoma received an injection of a special substance before imaging. The goal was to see if this method is safe an…

This study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …

This study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…

This study followed 26 adults with low-grade glioma who were receiving chemotherapy (temozolomide) for the first time after surgery. Researchers measured how the treatment affected patients' quality of life, thinking skills, and emotional well-being over one year. The goal was to…

This study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…

This completed phase 1 trial measured how much lidocaine, a common pain reliever, reaches the tumor and blood in 12 adults undergoing surgery for glioblastoma. Researchers collected blood and tumor samples at multiple times to understand the drug's levels. The goal was to gather …

This study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…

This study looked at whether a combination of two drugs (LY3214996 and abemaciclib) can reach brain tumors in people with recurrent glioblastoma, a type of aggressive brain cancer. About 42 participants took the drugs before surgery to remove their tumor, and researchers measured…

This completed study looked at whether stress and exercise levels influence survival and quality of life in 42 people with glioblastoma, a severe brain cancer. Participants wore a smartwatch to track heart rate, sleep, and activity, and filled out questionnaires on stress and fat…

This study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood…

This completed study looked at 90 adults with glial brain tumours to see if their quality of life and thinking abilities (like memory and focus) could help predict how long they live. Researchers used questionnaires and cognitive tests to track changes over time. The goal is to h…

This study looked at leftover tumor tissue and blood samples from 141 adults with glioblastoma or other solid tumors who were having surgery. The goal was to measure cell counts and viability to help scientists design better treatments for brain cancer and other solid tumors in t…

This study looks at how two common drugs—rifampicin (an antibiotic) and itraconazole (an antifungal)—affect the levels of a new cancer drug called BI 907828 in the blood. It involves 33 adults with advanced solid tumors who have not responded to previous treatments. Participants …

This study took leftover tumor tissue from 100 patients undergoing surgery for vestibular schwannoma (a non-cancerous brain tumor) and used it to grow stem cell organoids—tiny 3D versions of the tumor—in the lab. The goal was to create a living biobank to study why these tumors r…

This study looked back at 450 people who had surgery for a rare type of brain tumor (cerebellar glioma). Researchers wanted to see if where the tumor was located and its genetic makeup could predict how much of the tumor could be safely removed and how long patients lived. The go…

This completed study looked at 44 people with a type of brain tumor called glioma. Researchers used a special MRI scan to see if the swollen brain tissue around the tumor still had working connections. They then took small tissue samples during surgery to check if the scan result…

This French study asked 49 cancer patients how they felt about switching from hospital to home-based immunotherapy. The goal was to see if home treatment improved their satisfaction with care. It was an observational study, meaning no new treatments were tested—just patient exper…

This study tested two new methods to measure pressure and stiffness inside solid tumors in 27 patients. One method uses a thin catheter to measure pressure directly, and the other uses sound waves like an ultrasound to check stiffness. The goal was to see if these measurements co…

This completed Phase 2 study looked at 244 glioblastoma patients to see if platelet counts during radiation and chemotherapy could predict who would develop dangerously low platelets later. The goal was to create a monitoring plan for high-risk patients. No new drug or treatment …

This completed pilot study tested whether two types of brain scans—FDG PET and CT perfusion—can predict how well the drug bevacizumab works in people with recurrent glioblastoma, an aggressive brain cancer. Fourteen patients were scanned before treatment and then classified as re…

This study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after…

This pilot study tested whether a type of PET/CT scan (FDG PET/CT) can detect very early changes in glioblastoma tumors after starting chemotherapy. Seven patients with high-grade glioma were scanned shortly after beginning therapy to see if changes in glucose uptake could predic…

This study tested whether iPhones and Apple Watches can reliably collect health data from people with cancer. 49 adults undergoing cancer treatment wore an Apple Watch and used an iPhone for 4 months to track activity, fatigue, and thinking skills. The goal was to see if these de…

This study tested whether giving cancer patients a list of questions to ask their doctors helps them feel more empowered and less anxious. About 96 patients, along with nurses and doctors, took surveys and shared their experiences. The goal is to improve communication and make pa…

This completed study followed 183 cancer patients starting checkpoint inhibitor therapy to see how often they develop autoantibodies—proteins that can mistakenly attack the body's own tissues. Researchers collected blood samples to track changes in several types of autoantibodies…

This study tested whether an electronic diary app helps cancer patients take their oral medications more consistently than a traditional paper diary. A total of 124 adults with solid tumors or blood cancers were randomly assigned to use either the app or a paper diary to track th…

This registry collected information and biological samples from 354 children and young adults diagnosed with certain brain tumors like medulloblastoma and ependymoma. The goal was to improve diagnostic standards through expert review and to gather data for future research. No new…

This completed study looked at how well early COVID-19 antiviral therapies work in cancer patients. Researchers tracked 112 patients with solid tumors who received these treatments to see how many needed hospitalization within 14 days. The goal is to fill knowledge gaps and impro…

This study tested whether analyzing the DNA and RNA of a child's tumor could help doctors choose personalized treatments. It included 186 children with relapsed or hard-to-treat cancers like neuroblastoma and brain tumors. The goal was to see if this approach was feasible and saf…

This study looked at whether a special PET scan (18F-DOPA) can help doctors better see brain tumors when planning radiation therapy. 91 adults with newly diagnosed gliomas were enrolled. The goal was to see if this scan improves treatment planning and helps predict how well patie…

This early-phase study tested the safety and drug levels of belinostat in 17 patients with advanced solid tumors or blood cancers that had not responded to prior treatments. Researchers grouped patients by their UGT1A1 gene type to see if genetic differences affect how the drug i…

This study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing …

This completed Phase 2 trial tested whether a special PET/CT scan using 11C-methionine could help doctors better plan radiation therapy for people with glioblastoma, the most common and aggressive brain cancer. The study focused on patients whose tumors grew back quickly after su…

This study looked at whether a blood test measuring a protein called hPG80 (progastrin) can help track high-grade brain tumors like glioblastoma. Researchers took blood samples from 30 patients before, during, and after radiation and chemotherapy. The goal was to see if hPG80 lev…

This study looked at how bosentan, a drug that affects liver enzymes, changes the levels of the cancer drug lurbinectedin in the blood. Eleven adults with advanced solid tumors received lurbinectedin alone and with bosentan. The goal was to see if bosentan alters how the body pro…

This study created a registry of 149 cancer patients who received a precise type of radiation called SBRT. The goal was to track how doctors use this treatment in four different situations: for cancer that has spread to a few spots, after chemotherapy, before starting chemotherap…

This pilot study tested whether a special PET scan using 18F-FDOPA can help doctors better plan surgery and radiation for people with newly diagnosed brain tumors (gliomas). Twenty-four adults took part at Mayo Clinic. The goal was to see if the scan provides useful information b…

This Phase 1 study looked at how the antifungal drug itraconazole affects the levels of the cancer drug lurbinectedin in 14 patients with advanced solid tumors. The goal was to understand potential drug interactions, not to treat the cancer. Results may guide future dosing and sa…